Logotype for Sotera Health Company

Sotera Health Company (SHC) Investor Day 2024 summary

Event summary combining transcript, slides, and related documents.

Logotype for Sotera Health Company

Investor Day 2024 summary

8 Jul, 2026

Strategic priorities and market positioning

  • Focus on four key priorities: customer excellence, targeting growth markets, operational excellence, and disciplined capital allocation for incremental value creation.

  • Operates in large, highly regulated markets with high barriers to entry and strong customer relationships, with 70%+ revenue from multi-year contracts.

  • Emphasizes cross-business synergies, especially between Sterigenics and Nelson Labs, to drive integrated solutions and higher customer satisfaction.

  • Strategic segmentation targets higher-growth, higher-profitability areas such as diabetes, bioprocessing, wearables, and select pharma segments.

  • M&A remains a focus, with tuck-in and adjacent market acquisitions considered, but not included in current forecasts.

Financial performance and guidance

  • Achieved 8% CAGR in revenue and Adjusted EBITDA since 2020, with free cash flow growing at 10% CAGR.

  • Targets 5%-7% annual revenue growth and 5%-8% Adjusted EBITDA growth from 2025-2027, with $500M+ cumulative free cash flow and 35% EBITDA conversion by 2027.

  • Margin expansion of at least 50 basis points expected, driven by operational leverage and cost management.

  • CapEx to peak in 2025, then decline as major projects complete, supporting improved free cash flow.

  • Pricing tailwind adjusted to 3%-4% (from prior 3.5%-5%), mainly due to normalization in Nordion pricing.

Business unit highlights

  • Nelson Labs: Expanding pharma testing, investing in rapid testing and cleanrooms, and leveraging cross-business integration for growth and margin improvement.

  • Sterigenics: Leading global sterilization provider, investing $170M in EO facility upgrades to meet new regulations, and targeting mid- to high-single-digit growth.

  • Nordion: Global leader in Cobalt-60, securing long-term supply through investments in new reactor capabilities and exploring radiopharma opportunities.

  • All units benefit from durable customer relationships, high regulatory barriers, and integrated service offerings.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more